Ms. Anu Acharya, CEO, Ocimum Biosolutions says, “We are delighted to have Dr. David U’Prichard on our Board of Directors. David’s wealth of expertise in the biotech and pharma, venture capital and a strong academic background makes him a great source of wisdom for the road ahead for Ocimum. We look forward to a long and fruitful association with David.”

“With David joining, we now have a very formidable board that strengthens our already strong independent members like Dr. Anula Jayasuriya, Mario Gobbo and Mr. BVR Mohan Reddy.” Ms. Acharya added.

Dr. U’Prichard said, “I am very pleased to be joining the board of Ocimum, a company that is attaining leadership in the exciting space of integrated genomics, under the inspiring leadership of Anu Acharya. I have developed increasingly strong personal and business links in India over more than 15 years, and look forward to contributing to Ocimum’s continued success.”

Dr. David U’Prichard was the Chief Executive Officer and a member of the Board of Directors of 3-Dimensional Pharmaceuticals, Inc., Yardley PA (“3DP”) from 1999 to 2003. During his tenure at 3DP, he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D. From 1997 to 1999, Dr. U’Prichard served as Chairman of Research and Development at SmithKline Beecham, where he oversaw the entry of approximately ten compounds into global development. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997 as Executive Vice President and International Research Director from 1994 to 1997. Previously, Dr. U’Prichard was instrumental in the launch of Nova Pharmaceuticals in 1983, following an academic career as a tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School (1978-83), and his postdoctoral fellowship at Johns Hopkins University (1975-78). From 2003 to 2006, Dr. U’Prichard was a Venture Partner at Apax Partners Ltd. (London, UK) and Care Capital, LLC.

Dr. U’Prichard received his PhD in Pharmacology from the University of Kansas, and his B.Sc. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania, and is an Honorary Professor at the University of Glasgow. He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards. Dr. U’Prichard was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and has served on the boards of BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, and Ben Franklin Technology Partners of Southeastern Pennsylvania. Dr. U’Prichard is a Trustee of the International House of Philadelphia and was on the Board of the Bioethics Institute of the University of Pennsylvania.

Ocimum Biosolutions is a global integrated genomics services company with operations in Hyderabad, India, Gaithersburg, MD in the US and The Netherlands. Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers. Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

For more information, please visit www.ocimumbio.com

Hyderabad, India and Gaithersburg, MD, US | January 06, 2010: Ocimum Biosolutions, a leading integrated genomics company, today announced the launch of its ‘Pioneers in Genomics Education – Class of 2010’ program. The intention of this program is to cement a strong industry-academia-industry relationship and provide cutting-edge genomic tools and technologies to the budding world-class researchers of tomorrow from key institutions. The program also aims to build a model for cross-academic and cross-industry exchange of knowledge and ideas. This program would be launched for India first.

Ms. Anu Acharya, CEO, Ocimum Biosolutions, said, “There is an opportunity for all of us to make a positive difference to the educational framework.  The time has come for the industry to play a proactive role for creating an ecosystem and a platform for integrating basic research, education and applied research. This is going to happen when the industry takes a leadership role in identifying key stakeholders involved in cross-disciplinary life science education.”

“The Pioneers in Genomics Education Program is a definitive effort towards achieving this. Through this program, we are creating affordable access by opening up our widely used products to educational efforts through key stalwarts involved in life science education,” she added.

About the Program The Pioneers in Genomics Education Program is an effort to bring cutting edge industry genomics applications and tools into leading educational curriculum with an aim to reduce gaps between industrial discovery and basic research. Moreover, the Program helps to foster linkages with select leaders in education and assist in their training endeavor. The Program also creates a network and facilitates collaboration between participants of this Program. This Program also aims to give affordable access to cutting edge bioinformatics tools to current and future researchers and scientists in industry and academia. For more information, please check the link: http://www.ocimumbio.com/pge.

About Ocimum BiosolutionsOcimum Biosolutions is a global integrated genomics services company with operations in Hyderabad, India, Gaithersburg, MD in the US and The Netherlands. Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Hyderabad, India | Gaithersburg, Maryland USA – December 18, 2009: Ocimum Biosolutions, a leading integrated genomics company, today announced that it ranked Number 42 on the Deloitte Technology Fast 500 Asia Pacific 2009, a ranking of the 500 fastest growing technology companies in Asia Pacific. Rankings are based on percentage revenue growth over three years.  In addition to ranking on Deloitte’s Technology Fast 500, Ocimum ranked fourth on the Technology Fast 50 India Program, which is a ranking of the 50 fastest growing technology firms in India.

Earlier this year the INC magazine listed Ocimum as one the fastest growing companies in North America. Ocimum offers a global genomics infrastructure that includes GLP compliant labs, gold standard databases, biorepository and analytics on hosted data management platform.  The company is building a state-of-the-art facility at their corporate headquarters in Hyderabad which will mirror the GLP and CLIA facilities available in Gaithersburg.

Anu Acharya, CEO, Ocimum Biosolutions said that “We have always let customers’ needs drive our priorities. As the pharma and biotech industry evolves, the need for a global genomics infrastructure is desired. Ocimum has all the elements and we have created an infrastructure where we take on complete accountability to create consistent data for our customers.”

She added, “We are indebted to our growing list of global customers, who have trusted us over the years, referred us as partners in their R&D efforts. This has helped us continuously expand our portfolio and offer unique range of integrated solutions.”

“Being one of the 500 fastest growing technology companies in Asia Pacific is an impressive accomplishment. We commend Ocimum Biosolutions for making the Deloitte Technology Fast 500 Asia Pacific with a phenomenal 663% growth rate over five years,” said Yoshitaka Asaeda, partner in charge of Deloitte’s Technology Fast 500 Asia Pacific program.

Technology Fast 500 Asia Pacific Selection and Qualifications The Technology Fast 500 list is compiled from Deloitte’s Technology Fast 50 Asia Pacific programs, nominations submitted directly to the Technology Fast 500, and public company database research. To qualify for the Technology Fast 500, entrants must have had first year operating revenues of at least US$50,000.

Entrants must also be public or private companies headquartered in Asia Pacific and must be a “technology company,” defined as a company that owns proprietary technology that contributes to a significant portion of the company’s operating revenues; Manufactures a technology related product, or devotes a significant proportion of revenues to the research and development of technology.

About Ocimum Biosolutions

Ocimum Biosolutions is a global integrated genomics services company with operations in Hyderabad, India, Gaithersburg, MD in the US and The Netherlands.  Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry.  Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last four years by Deloitte Touche Tohmatsu.

For more information, please visit www.ocimumbio.com

About Deloitte

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 140 countries, Deloitte brings world-class capabilities and deep local expertise to help clients succeed wherever they operate. Deloitte’s more than 168,000 professionals are committed to becoming the standard of excellence.

Deloitte’s professionals are unified by a collaborative culture that fosters integrity, outstanding value to markets and clients, commitment to each other, and strength from cultural diversity. They enjoy an environment of continuous learning, challenging experiences, and enriching career opportunities. Deloitte’s professionals are dedicated to strengthening corporate responsibility, building public trust, and making a positive impact in their communities.

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu and its member firms.

Hyderabad, Andhra Pradesh, India, and Gaithersburg, Maryland, United States, December 01, 2009: Ocimum Biosolutions today announced the launch of Biotracker™ Lite, a general purpose version of its Life Sciences Specialty LIMS solution, Biotracker™.   Biotracker™ Lite is designed to meet the requirements of small to medium laboratories and offers a gamut of features including; managing samples and their associated data, inventory management, laboratory instrument management and integration, GLP and 21 CFR 11 compliance, ad-hoc and standard reports, and much more.  Biotracker™ Lite is an ideal solution for smaller labs that are looking for a robust, yet affordable automation solution to increase the efficiency and effectiveness of their laboratory processes.

“We are very excited about the release of Biotracker™ Lite”, said Howard Rosenberg, Executive Director – LIMS of Ocimum Biosolutions.  “Biotracker™ Lite is designed to addresses a currently underserved informatics market that needs flexible, out of the box laboratory and data management solutions at an affordable price”, continued Dr. Rosenberg.  “These small to medium sized labs will now be able to address their most pressing needs to automate and control their operations.”

For more details, please click on the following link: http://lims.ocimumbio.com/biotracker-lite

About Biotracker™ Lite

Biotracker™ Lite is an efficient LIMS solution for Sample Management, Data Management, Inventory Management and Instrument Management which is designed to satisfy the needs of small to medium laboratories.  Biotracker Lite enables users to easily manage samples and their associated data as well as tracking amounts, concentrations, availability, storage conditions and location of samples, reagents, enzymes, precursors, chemicals, labware, etc. available in an organization.  Additionally, Biotracker Lite provides an easy to use facility for managing laboratory instruments including their validation and maintenance records.  Utilizing Biotracker Lite will improve a lab’s performance and increase its efficiency and effectiveness.

For more details, please visit www.lims.ocimumbio.com.

About Ocimum Biosolutions

Ocimum Biosolutions is a global integrated genomics services company with operations in Hyderabad, India, Gaithersburg, MD in the US and The Netherlands. Ocimum provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over two-thirds of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Our global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®, we have developed expertise and capabilities that are unparalleled in the genomic services industry.  Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

For more information, please visit www.ocimumbio.com